Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego.

Mina Nikanjam,Jose Tinajero, Mary McGann,Jerry Li,Jincheng Yang,Felicity Shen,Jason K Sicklick,Shumei Kato,Edmund Capparelli,Razelle Kurzrock

Journal of hematology oncology pharmacy（2023）

引用 0|浏览55

暂无评分

摘要

Safe and tolerable dosing of novel combination therapies that includes trametinib, everolimus, or palbociclib is feasible for a precision medicine approach. However, neither results from this study nor results from previous studies could support the use of everolimus in combination with trametinib, even at reduced doses.

查看译文

关键词

adverse events,everolimus,molecular profiling,novel combination therapy,palbociclib,precision medicine,reduced dosing,safe dosing,solid tumors,tolerable dosing,trametinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要